Skip to main content
Clinical Trials/NL-OMON28713
NL-OMON28713
Recruiting
Not Applicable

A Double Blind, Randomized, Placebo Controlled,Multi-Center Trial of Anti-TNF¨¢Chimeric Monoclonal Antibody (Infliximab, Remicade®)in Combination with Methotrexate in Patients withVery Early Inflammatory Arthritis.

Josef S. Smolen MDDepartment of RheumatologyMedical University of ViennaWaehringer Guertel 18-20A-1090 Vienna, Austria+43-1-40400-4300josef.smolen@wienkav.at0 sites200 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Very early inflammatory arthritis.
Sponsor
Josef S. Smolen MDDepartment of RheumatologyMedical University of ViennaWaehringer Guertel 18-20A-1090 Vienna, Austria+43-1-40400-4300josef.smolen@wienkav.at
Enrollment
200
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Josef S. Smolen MDDepartment of RheumatologyMedical University of ViennaWaehringer Guertel 18-20A-1090 Vienna, Austria+43-1-40400-4300josef.smolen@wienkav.at

Eligibility Criteria

Inclusion Criteria

  • 1\. Men and women, \>\= 18 and \<\= 75 years of age, capable of understanding and signing an informed consent;
  • 2\. The presence of arthritis:

Exclusion Criteria

  • 1\. Have arthritis with a distinct diagnosis, made after a routine diagnostic work\-up
  • (examples are SLE, psoriatic arthritis, systemic sclerosis, gout, pseudogout, Lyme
  • arthritis, reactive arthritis, Parvo viral arthritis);

Outcomes

Primary Outcomes

Not specified

Similar Trials